Treatment trials

Overview: To evaluate the safety and tolerability of REGN10933+REGN10987 (Antibody interventional trial) compared to placebo. To evaluate the virologic efficacy (effectiveness) of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2.

Target population: Adult ≥ 18 years

Locations: Regeneron Study Site, Charleston; Regeneron Study Site, Clinton

Further information: Clinicaltrials.gov NCT04425629; 844-734-6643; clinicaltrials@regeneron.com

Overview: This study is to evaluate the safety, tolerability and efficacy of AT-527 in older subjects (ages 45-80 years) with moderate COVID-19 and risk factors of poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma).

Target population: Adults 45-80 years

Locations: Atea Study Site, Charleston; Atea Study Site, Columbia

Further information: Clinicaltrials.gov NCT04396106; 888-481-1607, ateaclinicaltrials@ateapharma.com

Overview: The purpose of this study is to measure how well LY3819253 works against the virus that causes COVID-19. LY3819253 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.

Target population: Adult ≥ 18 years

Location: VITALINK offices in Anderson, Gaffney, Greenville, Spartanburg, Union

Further information: Clinicaltrials.gov NCT04427501; 317-615-4559; ClinicalTrials.gov@lilly.com

Overview: A randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.

Target population: Adults ≥ 18 years and older

Locations: Columbia VA Health Care System

Further information: Clinicaltrials.gov NCT04439071; 866-562-4620, medinfo@ptcbio.com

Overview: The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path toward oxygen desaturation, ARDS, requirement for supplemental oxygenation, artificial ventilation or death in patients with COVID-19 on supplemental oxygen.

Target Population: Adults ≥ 18 years and older

Locations: Roper Hospital, Charleston

Further Information: Clinicaltrials.gov NCT04346615; 843-403-0227, chorne@lcids.com

Overview: The purpose of this study is to measure how well LY3819253, alone or in combination with either LY3832479 (LY-CoV016) or VIR-7831, works against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic or by phone. 

Target Population: Adults 18–64 years 

Locations: Vitalink- Anderson, Gaffney, Greenville, Spartanburg and Union 

Further Information: NCT04634409, 1-877-285-4559, clinicaltrials.gov@lilly.com 

Overview: A randomized, double-blind, placebo-controlled Phase 2 Study of LAU-7b against confirmed COVID-19 disease in hospitalized patients at a higher risk of complications. 

Target Population: Adults ≥ 18 years and older 

Locations: Roper St. Francis Healthcare, Charleston 

Further Information: Christine Horne, 843-402-0227, NCT04417257 

Overview: This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC. 

Target Population: Adults ≥ 18 years and older 

Locations: Medical University of South Carolina, Charleston 

Further Information: NCT04501978, tico@insight-trials.org (Type ACTIV-3 in subject line, do not include personal information in email.)  

Overview: The purpose of this study is to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19. 

Target Population: Adults ≥ 18 years and older 

Locations: Sage Investigational Site, Charleston 

Further Information: Ariel Brown, PhD, 617-949-4274, ariel.brown@sagerx.com

Overview: Drug studies often look at the effect one or two drugs have on a medical condition and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company in people who have tested positive for COVID-19 but who do not currently need hospitalization. This could help prevent disease progression to more serious symptoms and complications and spread of COVID-19 in the community. 

This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. Participants in the study will be treated with either a study drug or with placebo and will have 28 days of intensive follow-up after study drug administration, and then limited follow-up through 24 weeks. Study visits may be required after week 24 depending on the study agent. 

Target Population: Adults ≥ 18 years and older 

Locations: Medtrial, LLC, Columbia 

Further Information: Kaushlendra Tripathi, 803-254-4295, kt@medtrialsc.com, NCT04518410